To include your compound in the COVID-19 Resource Center, submit it here.

ChemoCentryx, GSK discontinue ChemR23 antagonist

ChemoCentryx Inc. (Mountain View, Calif.) said it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will discontinue development of CCX832 and

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE